Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) issued an announcement. Updated data from the Phase II trial of GFH375 single-agent treatment of KRASG12D mutant non-small cell lung cancer appeared in the oral report at the World Lung Cancer Conference (WCLC) held in Seoul this year on September 14, local time.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.